Vitruvian Partners, a European private equity firm focusing on leveraged buyout and growth capital investments in middle-market companies, completed the acquisition of a majority stake in KCAS Bioanalytical and Biomarker Services, a biotechnology company. Financial terms were not disclosed. “We are delighted to be working with Vitruvian as we look to advance both organic and inorganic plans to support the growing demand for our services. With additional capital, expertise, and a global reach, Vitruvian sets the stage for the organization to accelerate into the future as a prominent large molecule focused CRO services provider to the drug development industry. With heavy focus on talent acquisition and investment in capabilities for both technical and systems growth, we know that Vitruvian’s support and guidance will help enable our continued success. We look forward to continuing to grow our business with a very strong partner," John Bucksath, KCAS CEO.